Bayer invests 250 million USD in new cell therapy manufacturing facility in the U.S. Bayer AG has opened a new cell therapy production plant in Berkeley, California, USA, to bring cell therapies to patients on a global scale. The USD…
Promega to Develop Microsatellite Instability (MSI) Companion Diagnostic IVD Kit in Collaboration With GSK –Promega Corporation today announced it plans to develop and commercialize a microsatellite instability (MSI) companion diagnostic (CDx) IVD kit with GSK to identify adult cancer patients with…
Rockwell Medical Enters into 3-Year Product Purchase Agreement with Centers for Dialysis Care Rockwell Medical, Inc. (the “Company”) (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that…
Automata Technologies: $40m fundraise backed by Dimension and A.P. Moller Holding, to expand growing life science lab automation offering –Automata Technologies, a leading automation company powering life sciences labs, has raised $40m to accelerate its rapid growth and industry presence across…
Thought leaders at the Zayed Prize for Sustainable Development Forum chart paths forward to promote progress for people and planet The Zayed Prize for Sustainable Development, the UAE’s pioneering prize for sustainable and humanitarian development, held its second forum in…
Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Ligand Pharmaceuticals Incorporated announced that its partner Jazz Pharmaceuticals plc (Nasdaq: JAZZ), (“Jazz”) has been…
Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai…
Vividion Therapeutics starts Phase I clinical trial in advanced solid tumors with KEAP1 activator Vividion Therapeutics, Inc. (Vividion), announced today that it has initiated dosing of patients in a Phase I oncology clinical trial of its investigational oral Kelch-like ECH…
AstraZeneca advances UK clean heat and energy efficiencies with £100m commitment Powering AstraZeneca’s transition to net zero, the Company has agreed a 15-year partnership with Future Biogas to establish the UK’s first unsubsidised industrial-scale supply of biomethane gas, and is…
Takeda commits more than $30 million to five new global CSR partnerships to boost health impact in 92 countries Takeda today announces five new partnerships for its Global Corporate Social Responsibility (CSR) Program, which contribute to strengthening health systems in…
Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced…
AMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION Amgen and Horizon Therapeutics plc today announced the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take…